Results 41 to 50 of about 30,010,976 (156)

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells

Cell Communication and Signaling, 2021
Background Loss of the Ras GTPase-activating protein neurofibromin promotes nervous system tumor pathogenesis in patients with neurofibromatosis type 1 (NF1).
Shannon M. Weber, Nicole M. Brossier, Amanda Prechtl, Stephen Barnes, Landon S. Wilson, Stephanie N. Brosius, Jody Fromm Longo, Steven L. Carroll   +7 more
doaj   +1 more source

Accelerated long‐term forgetting in children with neurofibromatosis type 1

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To investigate the presence of accelerated long‐term forgetting after a 7‐day delay in children with neurofibromatosis type 1 (NF1), using an adapted verbal memory recall task, Experimental Word Recall Task (EWRT), and to examine its relationship with other cognitive abilities.
Jessica Habib, Melanie Porter, Jonathan M Payne, Shelley Arnold, Kristina M Haebich, Dinberu Shebeshi, Suncica Lah, Michael Gascoigne, Natalie A Pride   +8 more
wiley   +1 more source

Untersuchungen zur posttranslationalen Regulation von Neurofibromin

, 2002
Die Neurofibromatose Typ 1 (NF1) ist eine erbliche Tumorerkrankung mit benignen Tumoren, wie Neurofibromen, und einer erhöhten Inzidenz zu malignen Tumoren.
Müller, Ralf
core   +1 more source

A COMPREHENSIVE APPROACH TO THE STUDY OF PECULIAR PROPERTIES OF NEUROFIBROMATOSIS TYPE 1

Креативная хирургия и онкология, 2017
Having made a literature review, the writers of the article analyze the data of native and foreign researchers on the study of neurofibromatosis type 1.
R. N. Mustafin, M. A. Bermisheva, E. K. Khusnutdinova   +2 more
doaj   +1 more source

Periodontal Disease and Salivary Gland Dysfunction in Neurofibromatosis Type 1: A Case–Control Study

Oral Diseases, EarlyView.
ABSTRACT Objectives Neurofibromatosis type 1 (NF1) presents with diverse systemic and oral manifestations. The aim of this study was to investigate the periodontal status and salivary alterations in NF1 individuals. Methods A total of 38 individuals with NF1 diagnostic criteria were compared with a control group paired by age and sex.
Eloá Borges Luna, Gustavo de Souza Vieira, Flávia Lima Kleinsorgen Motta, Ana Beatriz Oliveira Gambôa, Analúcia Rampazzo Xavier, Rafaela Elvira Rozza‐de‐Menezes, Karin Soares Cunha   +6 more
wiley   +1 more source

The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation [PDF]

, 2016
Neurofibromatosis type 1 (NF1) and Legius syndrome are related diseases with partially overlapping symptoms caused by alterations of the tumor suppressor genes NF1 (encoding the protein neurofibromin) and SPRED1 (encoding sprouty-related, EVH1 domain ...
Dunzendorfer-Matt, Theresia, Scheffzek, Klaus, Mercado, Ellen L, Maly, Karl, McCormick, Frank   +4 more
core   +1 more source

Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells

Pharmaceutics
Neurofibromatosis Type 1 (NF1) is a common neurogenic condition characterized by heterozygous loss of function mutations in the neurofibromin gene. NF1 patients are susceptible to the development of neurofibromas, including plexiform neurofibromas (pNFs),
Bashnona Attiah, Garrett Alewine, Mary-Kate Easter, Robert A. Coover, Cale D. Fahrenholtz   +4 more
doaj   +1 more source

Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Glioblastoma (GBM) is the most aggressive form of primary brain cancer. Blood platelets have emerged as biomarkers where their RNA expression pattern indicates a tumor's presence. Our study aimed to characterize these patterns to identify biological processes associated with GBM and to evaluate their potential as a non‐invasive ...
Anna Giczewska, Krzysztof Pastuszak, Leon van Hout, Edward Post, Jip Ramaker, Ken Zwaan, Anna Supernat, Bart A. Westerman   +7 more
wiley   +1 more source

The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes

, 2003
Individuals with the neurofibromatosis 1 (NF1)-inherited tumor predisposition syndrome develop low-grade astrocytomas. TheNF1tumor suppressor gene product neurofibromin exhibits GTPase-activating activity (GAP) toward RAS, such that loss of neurofibromin
Biplab Dasgupta, Laura L. Dugan, David H. Gutmann   +2 more
core   +1 more source